Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Neurocrine Bioscienc
(NQ:
NBIX
)
127.06
-1.37 (-1.07%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Neurocrine Bioscienc
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Market Rally Mixed; Dow Jones Hits High While Nvidia Tumbles On Earnings: Weekly Review
August 30, 2024
The Dow Jones hit a new high while Nvidia led a Nasdaq retreat.
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
Why Neurocrine Biosciences Stock Was Tumbling This Week
August 30, 2024
The company promises to advance a top investigational drug to late-stage testing, but investors might not think that's a fine idea.
Via
The Motley Fool
Neurocrine Biosciences' Lower Dose Data Puts Its Schizophrenia Candidate In The Game, Analyst Upgrades Stock
August 29, 2024
Neurocrine Biosciences reports positive Phase 2 trial results for NBI-1117568 in adults with schizophrenia, showing significant reduction in PANSS scores with a 20 mg dose. Piper Sandler upgrades the...
Via
Benzinga
NVIDIA To Rally Over 31%? Here Are 10 Top Analyst Forecasts For Thursday
August 29, 2024
Via
Benzinga
Evaluating Neurocrine Biosciences: Insights From 15 Financial Analysts
August 19, 2024
Via
Benzinga
NASDAQ:NBIX—A High-Growth Stock Gearing Up for Its Next Upward Move.
August 19, 2024
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX): a strong growth stock preparing for the next leg up?.
Via
Chartmill
NASDAQ:NBIX is not too expensive for the growth it is showing.
August 19, 2024
Don't overlook NASDAQ:NBIX—a stock with solid growth prospects and a reasonable valuation.
Via
Chartmill
Nasdaq Down Over 1%; Foot Locker Shares Tumble After Q2 Results
August 28, 2024
Via
Benzinga
As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors
August 28, 2024
Neurocrine Biosciences reports Phase 2 trial results for NBI-1117568 showing significant improvement in schizophrenia symptoms, with an 18.2-point reduction in PANSS scores at a 20 mg dose.
Via
Benzinga
US Stocks Mixed; JM Smucker Slashes Annual Guidance
August 28, 2024
Via
Benzinga
Neurocrine Bio Dives As Schizophrenia Trial Results Lags Peers
August 28, 2024
As new schizophrenia drugs move toward approval, Neurocrine Biosciences reports a subpar outcome for its phase 2 trial.
Via
Investor's Business Daily
Regulators Expected To Approve Innovative Schizophrenia Treatment From Bristol Myers, Karuna
August 27, 2024
Drug companies are investing in schizophrenia treatments as patients are desperate for a drug that has few side effects, Bloomberg reports.
Via
Benzinga
A Closer Look at 7 Analyst Recommendations For Neurocrine Biosciences
August 01, 2024
Via
Benzinga
NASDAQ:NBIX, a strong growth stock, setting up for a breakout.
July 26, 2024
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX): a strong growth stock preparing for the next leg up?.
Via
Chartmill
NASDAQ:NBIX, a growth stock which is not overvalued.
July 26, 2024
Looking for growth without the hefty price tag? Consider NASDAQ:NBIX.
Via
Chartmill
Why the quality investor may take a look at NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX).
August 22, 2024
Is NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) suited for quality investing?
Via
Chartmill
9 Health Care Stocks Whale Activity In Today's Session
August 13, 2024
Via
Benzinga
New Study Reveals How Classical Music Could Revolutionize Depression Care
August 12, 2024
In a groundbreaking study, Chinese scientists have revealed that classical music could be a powerful tool in the fight against treatment-resistant depression, a condition that affects nearly 50% of...
Via
PressReach
Exposures
Product Safety
So Much For Expecting The Fed To Stick The Landing
August 04, 2024
Now is not the time to be fully invested.
Via
Talk Markets
Topics
Economy
Exposures
Interest Rates
Should Quality Investors Include NASDAQ:NBIX in Their Portfolio?
July 25, 2024
Why Quality Investors May Find NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Attractive.
Via
Chartmill
Cracking The Code: Understanding Analyst Reviews For Neurocrine Biosciences
July 10, 2024
Via
Benzinga
Stock Market Takes Bearish Turn; Apple, Microsoft, Meta, Amazon, AMD In Focus: Weekly Review
August 02, 2024
Apple and Meta had strong results, while AI spending remains robust.
Via
Investor's Business Daily
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Why NASDAQ:NBIX Is a Promising High-Growth Stock in the Midst of Consolidation.
July 05, 2024
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX), a strong growth stock, setting up for a breakout.
Via
Chartmill
NASDAQ:NBIX is not too expensive for the growth it is showing.
July 05, 2024
Don't overlook NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX)—a stock with solid growth prospects and a reasonable valuation.
Via
Chartmill
Reasonable Growth, Debt Levels, and a High ROIC Make NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Appealing to Quality Investors.
July 04, 2024
Why NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) qualifies as a quality stock.
Via
Chartmill
Despite its impressive fundamentals, NASDAQ:NBIX remains undervalued.
June 20, 2024
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX), an undervalued stock with good fundamentals.
Via
Chartmill
7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline
June 17, 2024
With biotech stocks enjoying a permanently relevant narrative, investors should focus on these compelling opportunities.
Via
InvestorPlace
Is NASDAQ:NBIX on the Verge of a Major Breakout as a Strong Growth Stock?
June 14, 2024
Is NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) on the Verge of a Major Breakout as a Strong Growth Stock?
Via
Chartmill
Neurocrine Biosciences Stock Tops Milestone Amid New Drug Plans
June 14, 2024
Neurocrine Biosciences has long been known for its blockbuster drug Ingrezza. It's diversifying, developing multiple drugs in related areas.
Via
Investor's Business Daily
Don't overlook NASDAQ:NBIX—a stock with solid growth prospects and a reasonable valuation.
June 13, 2024
Investors should take note ofNEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX), a growth stock that remains attractively priced.
Via
Chartmill
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.